Back to search

Article

Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer’s Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus Triggers

2025-03-17

Abstract excerpt

Alzheimer’s disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping pathological mechanisms, with DM2 increasing AD risk. Disease-modifying therapies (DMTs) for DM2, including Metformin and Semaglutide, have been explored for neuroprotection, yet their efficacy in AD remains unclear. Here, we introduce a novel integrative framework combining comparative network pharmacology, Mendelian Randomization (MR)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
53b114b8-6507-5af1-b0d8-b86edfd7fccf
DOI
10.1101/2025.03.14.643306
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer’s Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus TriggersDOI 10.1101/2025.03.14.643306
Molecular landscape of the overlap between Alzheimer’s disease and somatic insulin-related diseasesSemantic proximity
Causal association evaluation of diabetes with Alzheimer's disease and genetic analysis of antidiabetic drugs against Alzheimer's diseaseSemantic proximity
Two Birds With One Stone: The Protective Role of the Antidiabetic Drug Sodium-Glucose Cotransporter-2 Inhibitor in Neurodegenerative Diseases.Semantic proximity
Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation studySemantic proximity
Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomization studySemantic proximity
Multicomponent Mendelian randomization and machine learning studies of potential drug targets for neurodegenerative diseasesSemantic proximity
Evaluating the causal association between type 2 diabetes and Alzheimer's disease: a Two-Sample Mendelian Randomisation StudySemantic proximity
Cross-disease analysis of Alzheimer’s disease and type-2 Diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseasesSemantic proximity
Incidence and Risk of Alzheimer’s Disease in Individuals with Type 2 Diabetes: A Systematic Review and Meta-AnalysisSemantic proximity
Network-based Translation of GWAS Findings to Pathobiology and Drug Repurposing for Alzheimer’s DiseaseSemantic proximity
Drug repurposing of metformin for Alzheimer’s disease: Combining causal inference in medical records data and systems pharmacology for biomarker identificationSemantic proximity
The tissue-specific effects of glucose-lowering drug targets on aging mediated through DNA methylation: a multi-omics genetic studySemantic proximity
Select a neighboring publication to make it the new centre.